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University Health Network Toronto, ON, CanadaSummary cipal risk factors. From 60% to 90% of HCC-patients are diagnosedLiver transplantation is a well-established treatment in a
subset of patients with cirrhosis and hepatocellular carcinoma.
The Milan criteria (single nodule up to 5 cm, up to three nodules
none larger than 3 cm, with no evidence of extrahepatic spread or
macrovascular invasion) have been traditionally accepted as
standard of care. However, some groups have proposed that these
criteria are too restrictive, and exclude some patients from trans-
plantation who might beneﬁt from this procedure. Transplanting
patients with tumors beyond the established criteria falls into
two categories, those whose tumors are beyond the Milan criteria
at presentation without the use of treatment prior to transplanta-
tion (expanded criteria), and those in whom treatment allows the
Milan Criteria to be fulﬁlled (down-staging). Currently, however,
there is no international consensus regarding these approaches in
clinical practice. The purpose of this systematic review is to
clarify this debate through a critical analysis of available data.
Finally, some comments on predictive factors apart from
morphological characteristics are also addressed.
 2011 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.Background
Hepatocellular carcinoma (HCC) is a major health problem
worldwide, accounting for more than 1 million deaths annually
[1]. The incidence and mortality rates vary across different geo-
graphical areas because of the variation in incidence of the prin-Journal of Hepatology 20
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Criteria in Solid Tumors; DCP, des-gamma-carboxy-prothrombin.in association with liver cirrhosis, and the main risk factors are
chronic hepatitis B and C, alcohol abuse, and non-alcoholic fatty
liver disease [2]. Historically, HCC was usually diagnosed late in
the course of the disease and, consequently, the vast majority
of patients had a poor prognosis at diagnosis, with short survival
and high recurrence rates after treatment. Currently, however, as
a result of the implementation of screening programs and
advances in radiological assessment, an increasing proportion of
patients are diagnosed with early stage disease [3]. To date, it
is estimated that up to 30% of cases can be considered for treat-
ment with a curative intent [4]. Curative therapy includes liver
resection, percutaneous ablation, and liver transplantation (LT) [5,6].
LT has gradually found its role in the care of patients with HCC
and cirrhosis. Initially, the results of LT for HCC-patients were dis-
appointing with high recurrence rates and dismal patient survival
because of the advanced state of disease at the time of transplant
[7]. Therefore, the United Network for Organ Sharing (UNOS) con-
sidered HCC as a contraindication to LT, but indicated that it
would be necessary to deﬁne characteristics that might be asso-
ciated with better outcomes. In 1991, it was demonstrated that
patients who underwent LT for reasons other than HCC, and in
whom subsequent analysis of the explants identiﬁed incidental
HCC, had an outcome comparable to patients who underwent
LT for other indications [8]. In 1993, Bismuth et al. showed that
HCC-patients who on explant examination had no more than
two tumors none larger than 3 cm had good outcomes when sub-
mitted to LT [9]. Finally, in 1996 Mazzaferro et al. demonstrated
that patients with cirrhosis and a single HCC up to 5 cm, or up
to three tumors none larger than 3 cm, and without evidence of
macrovascular invasion or extrahepatic spread had a 4-year post
transplant survival similar to patients with non-malignant dis-
ease [10]. In this study, the tumor volume was assessed on the
basis of pre-transplant radiology. These criteria deﬁned a sub-
group of HCC-patients with relatively early disease, and became
known as the Milan Criteria (MC). Currently, the Guidelines of
the European Association for the Study of the Liver (EASL), and
the American Association for the Study of Liver Diseases (AASLD)
recommend that LT for HCC should be performed for patients
meeting these criteria [5,6].
In recent years, however, some groups have argued that the
MC are too restrictive, and exclude some HCC-patients from LT
despite the possibility of beneﬁt. Studies looking at liberalization
of the selection criteria for LT for HCC take two forms. One form
relates to transplantation of patients whose tumors are beyond
the MC without using pre-LT treatment (expanded criteria). The11 vol. 55 j 1137–1147
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second form involves the use of treatment to convert lesions that
exceed MC to lesions that are anatomically within the MC (down-
staging). Currently, however, there is no international consensus
about adopting these alternatives as standard of care [11,12]. The
purpose of this systematic review is to clarify this debate through
a critical analysis of available data. Moreover, the discussion of
further parameters beyond number and size of tumor is also
addressed.Data search methodology
A systematic search of Medline database was performed to iden-
tify studies evaluating expanded criteria and down-staging ther-
apy of hepatocellular carcinoma. The search was restricted to
papers written in English and published from 1995 to 2010.
The keywords used were hepatocellular carcinoma, HCC, liver
transplantation, LT, OLT, down-staging, expanded criteria, the
UCSF criteria, and Milan criteria. Only papers reporting cadaveric
liver donors that evaluated expanded criteria and down-staging
on the basis of tumor number and size were selected. This search
resulted in a total of 49 studies. Additionally, a full manual search
from bibliographies of papers describing aspects beyond tumor
number and size, and reports of consensus conference was also
performed.
The evidence for extending listing criteria beyond the Milan 
Criteria is poor. Yet it is clear that some patients with tumors 
beyond Milan Criteria may benefit from transplantation. 
Methods to identify those patients, and to identify patients with 
tumors within Milan Criteria who will do poorly are badly 
needed.  
Studies on downstaging are so heterogeneous as to make 
comparison impossible. Because the risk of poor outcomes is 
higher with larger tumours, the possibility of benefit is 
uncertain. Downstaging should therefore be reserved for 
experimental studies, primarily because of the potential effect 
on the non-HCC waiting list.  
Tumour size and number are relatively crude measures of 
prognosis. With the advent of molecular markers of tumour 
biology it is likely that in the future the implementation of 
predictors beyond tumor number and size will be incorporated 
into listing criteria to select HCC-patients for LT.
KeypointsSelection criteria for liver transplantation in HCC-patients
Transplanting HCC-patients with tumors beyond the Milan criteria
Expanded criteria (EC) can be deﬁned by the use of LT in recipi-
ents with tumors beyond the MC. The ﬁrst description was pub-
lished in 2001 by the group of the University of California, San
Francisco (UCSF) [13]. In their study, 70 HCC-patients who under-
went LT were retrospectively evaluated on the basis of explant
analysis, not pre-transplant radiology. In the 60 cases with either
a single nodule up to 6.5 cm, or up to three nodules none larger
than 4.5 cm, and total tumor diameter no more than 8 cm the
5-year overall survival was 75.2%. Forty-six out of the 60 patients1138 Journal of Hepatology 2011(76%) had tumors that were within the MC and these had a 5-year
survival of 72%. Subsequently, a number of different EC proposals
have been described (Table 1) [14–40]. However, the robustness
of the data among these studies deserves special attention in sev-
eral aspects.
Method of tumor assessment
Despite the recent advancements in radiological assessment of
liver masses [41], the risk of underestimating tumor burden is
still a major concern. Freeman et al. evaluated the results from
UNOS database on 789 LT recipients to determine the accuracy
of pre-LT imaging compared with explant features [42]. No
patients had received any treatment prior to LT, and at least
83% of cases were preoperatively staged through computed
tomography or magnetic resonance. Using the American Liver
Tumor Study Group TNM staging [43], radiology underestimated
tumor staging in 26.6% of cases. Furthermore, the risk of overes-
timation was almost 30%. The overall preoperative accuracy was
around 50%, regardless of the radiological technique used.
Whether this is due to inherent shortcomings of cross sectional
imaging techniques or to less than optimal protocols or interpre-
tive expertise is not clear. While this may not be important when
using MC, because the criteria allow some leeway, radiological
understating may be much more important when working at
the limits of what may be an acceptable size of lesion for trans-
plant, such as with the UCSF criteria. Of the studies shown in
Table 1, only four evaluated the risk of underestimating tumor
size separately in patients within the MC and beyond the MC
but within the proposed selection criteria [24,28,32,33]. The
Valencia proposal (up to three nodules, none larger than 5 cm,
and a cumulative tumor burden of 10 cm, without macrovascular
invasion or extrahepatic spread) showed that the preoperative
radiological assessment underestimated tumor size in 38.5% of
the cases beyond the MC, but only 17.3% in patients within the
MC (p = 0.014) [33]. Decaens et al. did a similar analysis using
the UCSF criteria [24]. Radiology underestimated tumor size in
48% of the cases beyond the MC and 34% in patients within the
UCSF criteria (p = 0.09). On the other hand, Yao et al. did not ﬁnd
higher rates of radiological underestimation when they compared
the MC with the UCSF proposal (p = 0.26). In this study the num-
ber of cases in the EC group was small, only 38 cases [28]. Finally,
Toso et al. showed that their proposal based on total tumor vol-
ume with a cutoff of 115 cm3 was more likely to result in correct
staging prior to LT when comparing patients with tumors within
the MC or within the UCSF criteria (91% vs. 69% and 75%, respec-
tively, p <0.001). Most importantly, various studies have shown
higher recurrence probability and worse survival in cases who
had tumors staged inaccurately [14,19,21,24,27,28,32,33,35,37].
The dilution effect
Whatever expanded proposal is analyzed, the impact of the dilu-
tion effect on outcomes is important and not fully accounted for.
For instance, the pioneer paper published by the UCSF group
described their results adopting an expanded proposal without
analyzing patients within and beyond the MC separately [13].
The dilution effect has a paramount role since both tumor recur-
rence and patient survival may be persuasive because of the
inclusion of cases having in theory the best characteristics such
as the group within the MC. In the original UCSF study, onlyvol. 55 j 1137–1147
Table 1. Results from studies evaluating down-staging for cadaveric liver transplantation for patients with cirrhosis and hepatocellular carcinoma.
Yao, 2001 [13]
UCSF Criteria
Herrero, 2001 [14]
Navarra Criteria
Roayaie, 2002 [15]
Khakhar, 2003 [16]
Fernández, 2003 [17]
Marsh, 2003 [18]
Pittsburgh Criteria
Ravaioli, 2004 [19]
Kneteman, 2004 [20]
 
Leung, 2004 [21]
Zavaglia, 2005 [22]
Löhe, 2005 [23]
Decaens, 2006 [24]
Onaca, 2007 [25]
Parfitt, 2007 [26]
Duffy, 2007 [27]
Yao, 2007 [28]
Jun, 2007 [29]
Suh, 2007 [30]
Herrero, 2008 [31]
 
Toso, 2008 [32]
Silva, 2008 [33]
Valencia Criteria
The 5-year survival in patients who met the USCF 
criteria was 75%, but this rate included the 46 cases 
fulfilling the MC as well.
Overall survival was similar between patients with and 
without HCC (p = 0.2).
All patients received routinely subselective TACE at 
the time of diagnosis, and intra-, and post-operative 
dose of doxorubicin.  
Patients without HCC (n = 935) presented a 5-year 
survival of 78%.
The UCSF criteria was a predictor of survival as well  
(p <0.5).
Stage IIIB: presence of microvascular invasion, bilobar 
tumors, any nodule >2 cm, without lymph node 
involvement nor extrahepatic spread.  
Only patients who survived longer than 1 year were 
studied. Milan criteria were predictor of higher survival 
rates.
All patients received sirolimus-based immunosuppres-
sion; nodules >5 cm radiology-based were biopsied, 
and patients exclude from LT in case of poorly differen-
tiated tumors.
Data from UNOS Region 1 Institutions. AFP levels 
were associated with both patient survival and 
recurrence rates. 
Poorly differentiated tumors and vascular invasion 
were the factors associated with poor survival rates.
Overall survival was higher in patients within the MC 
than beyond the MC (p <0.01), although the survival 
rates were not described in detail.
This is a multicenter study developed in 14 French LT 
institutions from 1985 to 1998; Five percent of the 
patients had no cirrhosis.
The subgroup of patients with tumors up to 1 nodule ≤6 
cm or 2-4 nodules ≤5 cm (n = 114) presented recurrence-
free survival similar to those patients within the MC.
UCSF criteria, AFP levels, and postoperative OKT3 
use were associated with poor survival rates. 
The mean follow up of 6.6 years was described in the 
role group analysed for 22 years. 
This was the first prospective validation radiology-
based from the UCSF group. 
Stage II:  presence of microvascular invasion, unilobar 
tumors, any nodule >2 cm, without lymph node 
involvement nor extrahepatic spread.    
Five out of the 24 patients beyond the MC had 
vascular invasion radiology-based.
Patients beyond the MC had a higher dropout risk.
Overall survival was similar in patients within the MC 
than beyond the MC in both radiology- (p = 0.3), and 
pathology-based (p = 0.2), although the survival rates 
were not described in detail in the paper. The 5-year 
survival was based upon personal communication.
The overall survival was similar survival between the 
arms within and beyond the Milan criteria.
1 nodule ≤6.5 cm;
2-3 nodules ≤4.5 cm;
tumor burden ≤8 cm
1 nodule ≤6 cm;
2-3 nodules ≤5 cm
Not defined
Not defined
Not defined
Pittsburgh Criteria
I-IIIB
Not defined
1 nodule <7.5 cm;
Multiple nodules 
<5 cm
UCSF criteria
Not defined
Not defined
UCSF criteria
Not defined
UCSF criteria
 
UCSF criteria
UCSF criteria
Pittsburgh Criteria I-II
 
Not defined
Navarra Criteria
Total tumor volume of 
115 cm3
1 nodule ≤5 cm;
2-3 nodules ≤5 cm;
tumor burden ≤10 cm
Retro
Pro
Pro
Retro
Retro
Retro
Retro
Pro
Retro
Retro
Retro
Retro
Retro
Retro
Retro
Pro
Retro
Retro
 
Pro
Retro
Retro
Pathology
Radiology 
Pathology
 
Radiology
Pathology
Pathology
Pathology
Radiology
Pathology
Radiology
Radiology
Pathology
Pathology
Pathology
Radiologya
Pathology
Pathology
Pathology
Radiology
Pathology
Radiology
Pathology
Radiology
Pathology
Radiologya 
Pathology
Radiology
 
Pathology
Radiologya
46
35
None
22
33
248
45
55
19
18
74
86
98
45
279
184
631
50
173
126
130
53
80
47
59
157
192
231
254
14
12
43
17
21
N/A
18
8
21
9
7
10
28
48
44
39
407
9
185
208
38
17
24
26
26
94
53
26
27
72
                 
N/A
N/A
70
68
67
73
78
87 at 4 ys
92 at 4 ys
51
N/A
74
N/A
60
70
62b
83
79
86
90b
77 at 3 ys
79 at 3 ys
70
66
82
77
62
56
N/A
N/A
N/A
24
54
N/A
67
38
83 at 4 ys
77 at 4 ys 
N/A
N/A
55
N/A
45
63
42b
15
64
71
93b
N/A
47 at 3 ys
56
68
77
72
69
66
Proposal Design Assessment
Within
MC
Beyond
MC
Within 
MC
Beyond 
MC
CommentsAuthor, year [Ref.] Number of Patients 5-year Survival (%)
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aIntention-to-treat principle.
bRecurrence-free survival.
MC, Milan criteria; UCSF, University of California, San Francisco; N/A, not available; HCC, hepatocellular carcinoma; TACE, transarterial chemoembolization, LT, liver
transplantation; UNOS, United Network for Organ Sharing; AFP, alpha-fetoprotein.
Table 1. (continued)
Mazzaferro, 2009 [34]
Metroticket Criteria
Pelletier, 2009 [35]
Fan, 2009 [36]
Shanghai Criteria
Chen, 2009 [37]
Toso, 2009 [38]
Gabrielli, 2010 [39]
Guiteau, 2010 [40]
The 71% 5-year survival rate among patients beyond 
the MC but within the proposed criteria was dependent 
on the absence of microvascular invasion.
Exploratory analysis from UNOS database; 30% of 
patients placed on WL as having HCC had no tumor 
data. 
Ten per cent of patients had no cirrhosis, four patients 
underwent living donor liver transplantation, and 85% 
of patients had chronic hepatitis B.
A multicenter exploratory analysis in Australia and 
New Zealand.
Data from the Scientific Registry of Transplant 
Recipients database; overall survival was similar in 
patients within the MC than beyond the MC but within 
UCSF (p = 0.6). The 3-year survival less than 50% 
was found among the 480 cases who presented with 
TTV >115 cm3 or AFP >400 ng/ml.
Patients within the MC had similar survival to without 
HCC. However, patients beyond the MC presented 
lower survival. 
UNOS region 4 multicenter study; it was not described 
the follow up among patients enrolled in the study, but 
given the short value, it was not possible to show the 
5-year overall survival.
Sum of the size of the 
largest nodule and the 
number of nodules ≤7 
(up-to-seven)
Not defined
1 nodule ≤9 cm;
2-3 nodules ≤5 cm;
tumor burden ≤9 cm
UCSF criteria
Total tumor volume of 
115 cm3
Not defined
1 nodule ≤6 cm;
2-3 nodules ≤5 cm;
tumor burden ≤9 cm
Retro
Retro
Retro
Retro
Retro
Retro
Pro
Pathology
Radiologya
Radiology
Pathology
Radiology
Pathology
Radiology
Pathology
Radiology
444
2790
N/A
394
108
117
6268
17
363
283
346
N/A
176
14
16
N/A
10
82
73
61
65
51
74
77
72 at 3 ys
94
73 at 3 ys
71
32
38
65
N/A
N/A
N/A
66
71 at 3 ys
Proposal Design Assessment
Within
MC
Beyond
MC
Within 
MC
Beyond 
MC
CommentsAuthor, year [Ref.] Number of Patients 5-year Survival (%)
Frontiers in Liver Transplantation24% of cases were beyond MC. As Table 1 shows, more recent
studies that have evaluated the possibility of expanding the MC
have taken this into account [16,17,19,20,24–28,30–36,39,40].
Upper tumor size limits
There is a general agreement among different proposals that
patients presenting macrovascular invasion or extrahepatic
spread should be excluded from LT given the unacceptable recur-
rence risk. Only the studies published by Roayaie et al. and Suh
et al. suggested that tumor involvement of portal branches was
not a contraindication to LT [15,30]. Given that the MC exclude
these characteristics, it is important that any new proposal for
EC describes in detail the speciﬁc proposal. A description of cases
as simply ‘‘beyond the MC’’ has only limited value because of the
lack of information about the exact features in this group. This
subset of patients could include cases with any single nodules
larger than 5 cm, any cases with two or three nodules larger than
3 cm, or any cases with more than three nodules. Unfortunately,
some of the papers described in Table 1 do not describe the
tumor upper limits. Studies from UCSF, Navarra, Alberta, Valen-
cia, Shanghai, the Metroticket study, and the UNOS Region 4
groups [13,14,32–34,36] do provide upper limits of tumor size.
Kneteman et al. also described an expanded proposal from the1140 Journal of Hepatology 2011Canadian Liver Transplant Study Group [20]. Adopting a siruli-
mus-based immunosuppression protocol, survival rates, and
tumor recurrence were compared between patients within
(n = 18) and beyond the MC (n = 9). Inclusion criteria were broad-
ened to include patients with single tumors up to 7.5 cm or any
number of tumors none larger than 5 cm in diameter. Patients
with tumors larger than 5 cm based on radiology were routinely
biopsied and excluded from LT if there was poor differentiation.
Despite similar long-term survival in both groups, given that
there was no restriction in tumor number, an absence of a
detailed description of tumor characteristics and a very small
sample size, this proposal needs to be cautiously interpreted.
Intention-to-treat principle
Dropout from the waiting list (WL) secondary to tumor progres-
sion has recently become an area of major relevance. Currently,
there are no well-deﬁned characteristics that predict who is more
likely to be removed from theWL as a result of tumor progression
beyond the listing criteria. The Barcelona group has shown that in
patients with tumors within MC, the 6-month cumulative proba-
bility of dropout was 11%, growing to 38% in the end of the ﬁrst
year on WL [44]. Additionally, it was demonstrated that if the
dropout rate is 25% at 12 months, the 5-year survival wasvol. 55 j 1137–1147
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60% based on the intention-to-treat principle (IIT), compared to
70–80% described for patients within the MC who actually get
transplanted. In the setting of EC, it could be argued that the
probability of dropout will be even higher as time goes by, when
compared with patients within the MC. Few studies have ana-
lyzed EC by the ITT principle [24,31,33,35]. Two of these papers
showed a 5-year survival rate less than 50%, a level that has been
considered as the lowest acceptable outcome [24,35]. Interest-
ingly, it is important to note that this phenomenon has already
been shown in a subset of patients with tumors within the MC.
Yao et al. showed that patients having single nodules larger than
3 cm, or more than one nodule presented a dropout probability
that was higher than those with a single nodule up to 3 cm
[45]. There are two approaches that can be considered. The ﬁrst
is to exclude patients with these adverse tumor characteristics
from transplant or alternatively prioritize these cases for early
LT. Furthermore, efforts should be made to identify factors asso-
ciated with dropout in order, once again, to prioritize these
patients for transplant. Of course, it could be that those factors
that predict dropout also predict worse prognosis after trans-
plant. This too requires study.
Study design
Most of EC proposals have been developed on the basis of retro-
spective studies [13,16–19,21–27,29,30,32–39]. Prospective study
design has been ranked higher in the hierarchy of evidence than
retrospective evaluation [46–48]. Themajor strength of a prospec-
tive cohort study is the accuracy of data collection with regards to
exposures, confounding factors, and outcomes, and restriction of
study participants to thosewith pre-deﬁned characteristics. Given
that themain concern related to the possibility of MC expansion is
the decrease in survival as a result of tumor recurrence, this event
may be underestimated using retrospective cohorts, since radio-
logical assessment is less likely to be performed strictly, and fol-
low-up may be incomplete. Thus, any proposal to expand the MC
should be ideally designed prospectively. Looking at Table 1, some
studies evaluated the use of more liberal criteria through a pro-
spective design. These will be commented on separately later.
Statistical power
The comparison between patients within and beyond MC may
show similar survival rates as a result of the analysis of an insuf-
ﬁcient number of patients to show true outcome differences.
There is no universal rule in order to calculate the number of
patients that should be followed. Dr. Andrew Burroughs has
recently performed a systematic review of patients who under-
went LT with tumors within the MC on the basis of radiology,
and showed that the expected 5-year survival was 64.9% (per-
sonal communication). Given that a 5-year survival of at least
50% is traditionally taken as the lowest acceptable result in the
setting of cadaveric LT [5,49], the minimum number of patients
could be calculated using the following assumptions:
 5-year survival of 64.9% in group within the MC;
 5-year survival of 50% in group beyond the MC but
within the EC proposal;
 Bi-directional analysis;
 Type I error rate alpha level of 5%;
 Type II error rate beta level of 20%.Journal of Hepatology 2011Adopting these parameters, sample size calculations require
at least 139 patients in each arm to perform an adequate eval-
uation. All negative results published so far from the compari-
son of these two independent arms could therefore be due to
the lack of statistic power, instead of representing a true sim-
ilarity between the groups. Additionally, it is pertinent to note
that this number of cases is in theory the smallest number that
can be used, because it uses the lowest acceptable results in
the group beyond the MC (50% at 5 years). If the acceptable
mortality rate at 5 years is higher, the sample size will
increase. Coincidently, this variation from 64.9% to 50% repre-
sents a relative difference around 25%. This magnitude of
change has been suggested as reasonable difference between
outcomes that can be used in clinical sample size calculation
without compound endpoints [46].
Evidence based medicine
There are various systems ranking publications in order to pro-
pose recommendations according to the robustness of data
available in a speciﬁc setting. The Oxford Center of Evidence-
based Medicine, the Newcastle-Ottawa Group, and the GRADE
Working Group are proposals that allow a comprehensive
review of the current evidence [50–52]. Regardless of the guide
used, meta-analysis and randomised controlled trials are the
highest levels of evidence. A fundamental concern related to
meta-analysis is to include only studies that are comparable
with regard to design, outcomes, and other epidemiological
points [53]. Despite the fact that there are statistical tools to
determine the degree of heterogeneity in papers selected for
a meta-analysis [54], the Cochrane Handbook for Systematic
Reviews of Interventions points out that the primary inclusion
criterion for studies must be linked to clinical judgement
related to the speciﬁc topic to be evaluated [53]. The analysis
of the design characteristics of existing studies summarized
in Table 1 suggests that there is too much heterogeneity to
consider meta-analysis at the moment. Randomised controlled
trials in the setting of potentially life-saving therapy such a
LT are theoretically possible, but in practice likely very difﬁcult
to conduct. An alternate study design to validate any EC pro-
posal might be based on:
 Radiological assessment properly performed;
 Prospective design;
 Comparison between patients within the MC and beyond
the MC but within the new proposal;
 Overall survival as the primary endpoint [4];
 An estimated number of patients of at least 139 patients
in each arm.
Looking at the studies shown in Table 1, it is clear that some
concerns persist. Only three series approach the study design
described above [14,28,40], but even these have signiﬁcant
design ﬂaws. Herrero et al. analyzed only 24 patients in the
beyond MC group but within the Navarra criteria, and the study
design and the precise radiological characteristics of tumors are
not clearly described. Yao et al. reported their experience in 38
patients beyond the MC but within the UCSF criteria, but fol-
lowed these patients for a median of only 26 months, and they
did not report the overall survival between the groups, only
recurrence-free survival. It is well accepted that the overallvol. 55 j 1137–1147 1141
Table 2. Results from studies evaluating expanded criteria for cadaveric liver transplantation for patients with cirrhosis and hepatocellular carcinoma.
Majno,
1997 [55]
Graziadei,
2003 [56]
Yao, 2008 
[57] UCSF 
DS criteria
Ravaioli, 
2008 [58]
Bologna 
criteria
Chapman,
2008 [59]
 
Lewandowski,
2009 [60]
De Luna,
2009 [61] 
Barakat, 
2010 [62]
Jang, 
2010 [63]
This study evaluated only patients who in 
fact underwent LT. The analysis only in 
patients beyond the MC was not performed. 
Regardless of DS response, all the 54 
patients enrolled underwent LT. 
Forty-eight HCC-patients initially staged 
within the MC had 5-year IIT survival of 94% 
(41 were transplanted).  
 
Baseline tumor stage based on 
AASLD/EASL guidelines. A minimum 
observation period of 3 months was needed 
before LT.
Baseline tumor stage based on 
AASLD/EASL guidelines. Eight-eight 
HCC-patients initially staged within the MC 
had 3-year recurrence-free survival similar 
to the DS group.  A minimum observation 
period of 3 months was needed before LT. 
Transplanted patients were followed for 19 
months post-LT. IV A ALTSG stage includes 
cases with any tumor number and size plus 
gross intrahepatic portal vein involvement or 
hepatic vein involvement. 
The study was primary designed to compare 
the rates of DS treated with TACE versus 
TARE-Y90. Apart from LT, liver resection 
was also considered as a curative therapy 
post-DS.
Overall survival was similar to 95 patients 
placed on waiting list within the MC (p = 0.9).
The DS treatment was chosen following a 
multidisciplinary meeting taking into account 
tumor and patient characteristics. 
The subset of patients with a single nodule 
up to 7 cm who achieved complete necrosis 
with AFP <100 ng/ml had lower tumor 
recurrence post-LT (p = 0.04) 
Retro
Pro
Pro
Pro
Pro
Retro
Retro
Retro
Retro
Not defined
Absence of 
extrahepatic spread 
and vascular 
invasion
1 nodule ≤8 cm;
2-3 nodules ≤5 cm;
4-5 nodules ≤3 cm;
sum diameter ≤8 cm
1 nodule ≤6 cm;
2 nodules ≤5 cm;
<6 nodules ≤4 cm;
sum diameter ≤12 
cm
ALTSG stage
III e IV A 
UNOS T3 tumors
Not defined 
Unlimited tumor 
number and size, 
but with no vascular 
invasion or 
extrahepatic spread 
Not defined
Absence of 
extrahepatic spread
Tumor size reduction 
of at least 50% 
(hypervascular area)
MC 
MC and AFP <400 
ng/ml
 
MC
MC
MC
MC
MC
TACE
TACE
TACE
RAFE
Resection
PEI
TACE
RAFE
Resection
PEI
 
TACE
TACE
TARE-Y90 
TACI
TACE
RAFE
TARE-Y90
Resection
TACL
n = 54
n = 15
n = 61
n = 48
n = 76
n = 43
n = 43
n = 27
n = 32
n = 386
51
50
 
70
 
90
23
31
58
63
56
41
67a
41 at 4 ys
92 at 4 ys
71 at 3 ysa
94
19 at 3 ys
59 at 3 ys
84 at 3 ys 
75 at 2 ys 
56 at 5 ys
n = 54
n = 10
n = 35
(LDLT
n = 2)
67%
 
n = 17
n = 11
n = 9
n = 15
n = 14
n = 37
(LDLT
n = 30)
Design Selection
to DS
Criteria 
for LT
DS
treatment
Patients 
DS
DS 
success
rate (%) 
Trans-
planted
5-Survival
(%)
CommentsAuthor, year
[Ref.]
aDisease-free survival.
DS, down-staging; LT, liver transplantation; MC, Milan criteria; TACE, transarterial chemoembolization; HCC, hepatocellular carcinoma; ITT, intention-to-treat; UCSF,
University of California, San Francisco; RAFE, radiofrequency ablation; PEI, percutaneous ethanol injection; LDLT, living donor liver transplantation; AASLD, American
Association for the Study of Liver Diseases; EASL, European Association for the Study of the Liver; ALTSG, American Liver Tumor Study Group (reference 43); TARE,
transarterial radioembolization; TACI, transcatheter arterial chemoinfusion; TARE-Y90, transarterial radioembolization with Yttrium-90; TACL, transarterial chemo-
lipiodolization; AFP, alpha-fetoprotein.
Frontiers in Liver Transplantationsurvival is the main important outcome in phase III clinical trials,
including speciﬁcally recommendations regarding HCC [4,5].
Finally, Guiteau et al. evaluated the results of a new proposal
adopted in the UNOS Region 4 (single nodule up to 6 cm, up to
three nodules up to 5 cm, and a cumulative tumor burden of
9 cm) in 82 cases. Despite the appropriate design of this study,
its main limitation was the short follow up. This study only
followed patients for 3 years.1142 Journal of Hepatology 2011An alternative method to validate an EC proposal is to evalu-
ate a large cohort of patients identifying factors associated with
different durations of survival. Mazzaferro et al. [34] recently
published an international retrospective exploratory analysis
only including cases beyond the MC on the basis of explant
assessment. Among the 1112 cases enrolled, the subset of
patients who had tumors within the up-to-seven criteria (HCC’s
with seven as the maximum score based on adding the diametervol. 55 j 1137–1147
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of the largest tumors to the total number of tumors), without
microvascular invasion, achieved a 71.2% 5-year overall survival.
Despite the fact that the inherent concerns already commented
on, such as tumor size assessment on the explant rather than
pre-transplant radiology, this study does improve our under-
standing of EC.
Transplanting HCC-patients with tumors beyond the conventional
criteria using preoperative techniques to fulﬁll more selective criteria
on the basis of tumor number and size
The term ‘‘down-staging’’ (DS) can be deﬁned as the use of any sort
of treatment prior to LT in patients who have tumors beyond the
MC in order to reduce tumor stage to be eligible for LT. Majno
et al. presented the ﬁrst experience using DS in HCC-patients in
1997. In a retrospective study, they showed higher survival rates
in HCC patients treated with trans-arterial chemoembolization
(TACE) and who responded, than in those who did not respond to
TACE. The cohort consisted of patients with HCC larger than 3 cm
or more than three nodules [55]. Subsequent studies that have
beenpublishedon theuse ofDS in the setting of LT are summarized
in Table 2 [56–63]. All the concerns already discussed in relation to
EC can be applied to DS as well. In addition, there are other issues
speciﬁcally related to DS that need to be taken into account.
Listing criteria
Both macrovascular invasion and extrahepatic spread are well
established strong predictors of poor patient survival because of
an unacceptably high risk of recurrence. With the exception of
the study published by Chapman et al. [59], all other studies on
DS excluded patients who had either macrovascular invasion or
poor tumor differentiation. Currently, the discussion regarding
the entry criteria for DS is based on tumor number and size
beyond the MC. However, there is very good evidence that fea-
tures other than tumor size, such as the degree of differentiation
and the presence of microvascular invasion are major predictors
of outcomes, and that the likelihood of these characteristics being
present increases with tumor size [64,65]. In Table 2, it can be
noted that only two studies clearly describe the entry character-
istics of the patients. The UCSF proposal included a single tumor
up to 8 cm, up to ﬁve tumors none larger than 3 cm, and a cumu-
lative maximum tumor diameter of 8 cm [57]. Forty-three out of
the 61 patients had successful DS to within the MC and 41 cases
underwent LT with a 4-year survival of 92%. In the Bologna study,
the upper limits were a single nodule up to 8 cm, two nodules up
to 5 cm, up to ﬁve nodules none larger than 4 cm, and a cumula-
tive maximum tumor diameter of 12 cm [58]. Forty-eight
patients underwent DS to within the MC. This was associated
with an alpha-fetoprotein (AFP) level lower than 400 ng/ml and
the 32 cases who were submitted to LT had a 3-year survival of
71%. The clear documentation of upper tumor limits is of funda-
mental importance in the DS setting and the lack of this informa-
tion in almost all published studies is a major deﬁciency in
interpreting these studies.
Down-staging technique
The different techniques used to achieve DS include TACE
[55–60,62,63], radiofrequency ablation [57,58,62], arterial chemo-
infusion [61], percutaneous ethanol injection [57,58], resectionJournal of Hepatology 2011[57,58,62], and radio embolization [60,62]. The majority of
the studies summarized in Table 2 evaluated DS adopting a
combination of various treatment protocols, often simply using
what was standard for that institution and particular patient
characteristics.
To date, there have been no external validation studies
of any proposed DS alternatives. Given the heterogeneity of
treatments used in DS, none of the studies can be considered
deﬁnitive, and the results of all the studies must be interpreted
cautiously.
Down-staging efﬁcacy assessment
The response to DS treatment has to be based on radiological
measurement of tumor characteristics. Some of the difﬁculties
in accuracy of radiology have already been discussed. The
Response Evaluation Criteria in Solid Tumors (RECIST) has been
traditionally used to deﬁne response to DS [59]. However, the
RECIST criteria may not be adequate in this scenario. RECIST con-
siders only tumor diameter, and does not take into account the
areas of necrosis or the assessment of viability of tumor [66].
The EASL HCC guidelines suggested that assessment of tumor
response should consider only the area of viable tumor [67,68],
deﬁned by arterial enhancement on a radiological contrast study.
Although this was also endorsed by the AASLD guidelines, many
studies report only RECIST criteria [56,59,61,63].
Moreover, it has recently been suggested that there should be
a period of at least 3 months from the date on which the imaging
study shows HCC to be within the MC after DS treatment before
undertaking transplant [69]. This interval would help to identify
tumors with unfavorable biology and, consequently, avoiding LT
in HCC patients with more aggressive tumors who would not
beneﬁt from this procedure. This strategy has been described
by several authors [57–59], but its effect on outcomes has not
been assessed in comparative studies.
The best strategy to evaluate the use of DS in clinical practice
would be to conduct a multicenter and prospective cohort study
targeted at downstaging HCC to within MC, with a control arm
initially within the MC, adopting a standard DS protocol, i.e.,
standard diagnostic and staging tests, the clear establishment of
upper tumor limits, the use of a standard DS technique for all
patients and standard follow-up. Finally, the criteria to de-list
patients who had been successfully down-staged but thereafter
progressed beyond the acceptable criteria, as well as whether
these patients might be re-listed following additional treatment
have to be deﬁned. For the majority of the studies that describe
DS, tumor progression beyond the proposed down-staged criteria
excludes patients from transplantation. This restriction has been
applied to extended criteria as well, i.e., progression beyond the
limits of the extended criteria is a reason to de-list the patient.
Additional parameters such as TACE responsiveness and AFP level
on WL have been proposed as an alternative tool in this setting
[70–72]. Nevertheless, there are no robust data, and further stud-
ies are once again warranted.Beyond tumor number and size
Apart frommorphological characteristics, a number of alternative
factors have been described as markers of tumor aggressiveness
and risk of recurrence. These include response to TACE [70,71],vol. 55 j 1137–1147 1143
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the degree of differentiation [20,73,74], the gene-expression
proﬁle [75–77], the presence of microvascular invasion [78],
and the AFP levels [72,79–81].Treatment responsiveness
Otto et al. [70] performed TACE in 96 HCC-patients to evaluate
the impact of TACE-responsiveness on outcome post-LT.
Sixty-two out of 96 patients had tumors beyond the MC before
undergoing the initial TACE. Patients meeting the MC were
immediately placed on WL, whereas cases beyond the MC were
included on WL only after achieving at least a partial response
by RECIST criteria (30% decrease in the sum of the largest diam-
eter of ﬁve target lesions, taking as reference the baseline sum of
the largest diameter). Fifty patients ﬁnally underwent LT, of
whom 34 were in the group beyond the MC. The 5-year recur-
rence-free survival was similar in patients within and beyond
the MC who responded to TACE, (93% vs. 74%, p = 0.42). When
all transplanted patients were considered (n = 50), TACE-respon-
siveness was associated with improved patient survival, whereas
survival was not related to whether the patients were within or
beyond MC. However, the small sample size again makes these
results hard to interpret.
Millonig et al. [71] published their experience using TACE in
116 HCC-patients in order to avoid tumor dropout beyond the
UCSF criteria. One hundred and six out of the 116 cases enrolled
underwent LT. According to the modiﬁed-RECIST criteria pro-
posed in the 2001 EASL guidelines [5], patients with partial
response (devascularisation of at least 30%) or complete response
(no viable tumor) had better 5-year survival rates than patients
who did not respond to TACE (62%, 93%, and 19%, respectively,
p <0.001). However, in contrast to previous results, the subgroup
analysis revealed that the usefulness of TACE-responsiveness was
only associated with patients who were initially staged as having
tumors within the MC, not the UCSF criteria. These data have to
be conﬁrmed in properly designed studies, but they do indicate
that biologic characteristics such as response to treatment may
be in the future incorporated into the selection criteria in HCC-
patients for LT.Degree of differentiation
In 2004, Cillo et al. [73] evaluated the results of LT in 48 patients
who did not have poorly differentiated tumors on biopsy per-
formed pre-LT. They found a 5-year survival rate of 75%, indepen-
dent of the number or size of the lesions. Recently, the same
group updated their experience [74], evaluating their results on
the basis of the ITT principle, and comparing the survival rates
between the cases within (n = 60) and beyond (n = 40) the MC,
still considering only cases with moderately or well differentiated
tumors. There was no signiﬁcant difference in the 5-year survival
between the groups (69% vs. 79%, respectively). Using a similar
strategy, Kneteman et al. [20] also showed the results of exclud-
ing cases with tumors larger than 5 cm with a poor degree of dif-
ferentiation on biopsy prior to LT. The feasibility of adopting this
approach to clinical practice has been challenged since biopsy
samples may be misleading [82]. HCC is notoriously heteroge-
neous histologically, and a biopsy may easily miss the areas of
poor differentiation, resulting in a misclassiﬁcation of the lesion
as moderately or well differentiated.1144 Journal of Hepatology 2011Gene-expression proﬁle
Recently, the role of genetic markers in HCC has come under
scrutiny [75–77]. In the speciﬁc setting of LT for HCC, little is
known. Schwartz et al. described a technique for detecting the
allelic imbalance near tumor oncogene loci as an attempt to
deﬁne molecular markers predictive of HCC recurrence after LT
[77]. Seventy HCC-patients who underwent LT were evaluated
(35 within the MC and 35 beyond the MC). Twenty-four out of
the 70 patients (34%) developed tumor recurrence after a median
follow-up of 12.5 months. Allelic imbalance was signiﬁcantly
associated with recurrence for nine out of the 18 satellites stud-
ied. The cases who developed tumor recurrence after LT had sig-
niﬁcantly higher fractional allelic imbalance with a cut off of 0.27
(75% vs. 5%, respectively) regardless of whether the tumor was
within or beyond the MC. Importantly, this study was performed
on the analysis of explants characteristics. Thus, these ﬁndings
should be still validated through the sample obtained from biop-
sies before LT.
Microvascular invasion
It is well-known that microvascular invasion is associated with
worse survival and an increased risk of recurrence post LT [4,5].
Despite some promising attempts to identify microvascular inva-
sion before LT through imaging modalities [83,84], to date there
is no reliable way to identify microvascular invasion pre-LT. Con-
sequently, attempts to identify pre-LT markers associated with
microvascular invasion are now being investigated. Shirabe
et al. measured des-gamma-carboxy-prothrombin (DCP) in the
serum of patients with HCC in the non-transplant setting and
found a correlation between an increased concentration of this
marker and the presence of microvascular invasion, with a rela-
tively high speciﬁcity of 85%. This ﬁnding has been conﬁrmed
by Koike et al. who, in addition, demonstrated that DCP level
was the strongest predictive factor that correlated with the late
development of tumor recurrence following treatment based on
various forms of percutaneous ablation [85]. The usefulness of
DCP as a reliable parameter associated with microvascular inva-
sion has been suggested mostly in Japanese studies. Therefore,
an international multicenter validation is required to assess the
predictive value of this parameter.
Alpha-fetoprotein levels
Recently, some investigators have proposed that AFP values
might play a role in selecting HCC-patients for LT [38,79–81].
Once again, in the non-transplant setting, an elevated AFP is a
marker of more advanced disease. An increase in AFP concentra-
tion might reﬂect tumor aggressiveness including differentiation
degree and vascular invasion and, consequently lead to a higher
risk of tumor recurrence. Toso et al. performed an overview of
adult recipients in the Scientiﬁc Registry of Transplant Recipients
from March 2002 to January 2008 [38]. Among the enrolled
patients, 6268 had tumors within the MC on the basis of
radiology. In the multivariate analysis, it was shown that high
AFP levels and TTV >115 cm3 were associated with poor long-
term survival. The 480 patients who presented with either
TTV >115 cm3 (n = 13) or AFP >400 ng/ml had a 3-year survival
lower than 50%. The progression of AFP levels while on WL has
also been addressed [72]. Using receiver operating characteristicsvol. 55 j 1137–1147
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curve analysis for recurrence after LT, Vibert et al. showed that
16% of HCC-patients who had an AFP increase >15 ng/ml per
month while on WL (n = 26) had worse post transplant survival
that those in whom the AFP rise was absent or less than
15 ng/ml/month. The authors concluded that the AFP progression
during the WL could be incorporated as a preoperative marker of
tumor aggressiveness.
The above strategies involving markers of tumor biology all
require additional validation. Nevertheless, it is clear that other
parameters beyond tumor size and number are important, and
should play a role in the selection of HCC patients for LT.Conclusions
Given that untreated HCC-patients diagnosed at early stages have
a 5-year survival of approximately 20% [86], it is clear that both
EC and DS provide beneﬁt for individual patients, when com-
pared to no therapy. Whereas with other cancer treatments, this
degree of success would result in a change in practice, liver trans-
plant cannot be considered in the same way. The persistent
severe shortage of donor organs means that the importance of
deriving maximum beneﬁt from this valuable community
resource has to be taken into account. Recently, Volk et al.
showed that the adoption of more liberal criteria would lead to
an increase of 44% risk of death among all patients on the WL
(not just the HCC patients) [87]. In addition, it was estimated that
a higher threshold of 61% 5-year survival is necessary to justify
the use of a more liberal approach for listing HCC-patients
beyond the MC at least in speciﬁc regions of the United States
with severe organ shortage. The possibility of adopting more lib-
eral selection criteria for HCC patients poses a dilemma. The
acceptance of a more liberal organ allocation policy may result
in denying the use of these organs to other patients for whom
better results may be achieved. On the other hand, not accepting
these criteria condemns individuals to non-curative therapies
and denies them a treatment which may prolong their survival.
This dilemma clearly demonstrates the importance of further,
well designed studies that may overcome this paramount issue.Conﬂict of interest
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